NasdaqCM - Nasdaq Real Time Price USD

Precision BioSciences, Inc. (DTIL)

4.8800

+0.1900

+(4.05%)

At close: May 20 at 4:00:01 PM EDT

Sidoti Events, LLC's Virtual May Micro-Cap Conference

NEW YORK, NY / ACCESS Newswire / May 20, 2025 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day May Micro-Cap Conference taking place Wednesday and Thursday, May 21-22, ...

ACCESS Newswire 20 hours ago

GATX

GSIT

TNMG
Precision BioSciences (DTIL) Reports Q1 Loss, Lags Revenue Estimates

Precision BioSciences (DTIL) delivered earnings and revenue surprises of -413.95% and 99.71%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 5 days ago

DTIL
+4.05%
Precision BioSciences: Q1 Earnings Snapshot

DURHAM, N.C. (AP) — Precision BioSciences Inc. DTIL) on Thursday reported a loss of $20.6 million in its first quarter. On a per-share basis, the Durham, North Carolina-based company said it had a loss of $2.21.

Associated Press Finance 5 days ago

DTIL
+4.05%
Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update

DURHAM, N.C., May 15, 2025--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced financial results for the first quarter ended March 31, 2025, and provided a business update.

Business Wire 5 days ago

DTIL
+4.05%
Precision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

DURHAM, N.C., May 14, 2025--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced the strategic prioritization and acceleration of PBGENE-DMD, the Company’s first-in-class in vivo gene editing approach for Duchenne Muscular Dystrophy (DMD) and highlighted a PBGENE-DMD poster presentation at the American Society of Gene and Cell T

Business Wire 6 days ago

DTIL
+4.05%
Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025

DURHAM, N.C., May 08, 2025--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that it will publish financial results for the first quarter 2025 and provide a business update on May 15, 2025.

Business Wire 12 days ago

DTIL
+4.05%
Precision BioSciences Announces Presentation of Initial Safety Data from the Phase 1 ELIMINATE-B Trial Evaluating PBGENE-HBV at the 2025 European Association for the Study of the Liver Congress (EASL)

DURHAM, N.C., May 07, 2025--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that it will present initial safety data from the Phase 1 ELIMINATE-B trial evaluating PBGENE-HBV program for the treatment of chronic hepatitis B during a late breaking poster presentation at the European Association for the Study of the Liver (EAS

Business Wire 13 days ago

DTIL
+4.05%
Precision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

DURHAM, N.C., May 01, 2025--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, including gene elimination, gene insertion, and gene excision programs, today announced that five abstracts detailing Precision’s wholly owned or partnered programs have been accepted for presentation at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting being held May 13-17, 2025

Business Wire 19 days ago

DTIL
+4.05%
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

DURHAM, N.C., April 29, 2025--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that, on April 22, 2025, the Compensation Committee of Precision’s Board of Directors approved the grant of inducement awards to new employees under the Precision BioSciences, Inc. 2021 Employment Inducement Incentive Award Plan ("Inducement Award

Business Wire 21 days ago

DTIL
+4.05%
DTIL Gets FDA's Fast Track Tag for Hepatitis B Gene Therapy, Stock Up

Precision BioSciences stock soars 24% as the FDA grants the Fast Track designation to its PBGENE-HBV gene therapy for potentially curing chronic hepatitis B.

Zacks last month

DTIL
+4.05%
Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B

DURHAM, N.C., April 15, 2025--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for PBGENE-HBV, the Company’s lead wholly owned in vivo gene editing program designed to cure chronic hepatitis B by eliminating cccDNA, the key source of replicat

Business Wire last month

DTIL
+4.05%
Biotech stocks slide as Marks resignation seen being negative for sector

Shares of several biotech and biopharma names are under pressure on Monday following the resignation of the head of the Food and Drug Administration’s Center for Biologics Evaluation and Research, Peter Marks. RBC Capital says the development is “not good for the biotech industry even beyond vaccines.” Voicing a similar opinion, BMO Capital told investors this morning that it sees the news as a “significant negative” for the biopharma and biotech sectors. “NOT GOOD” FOR BIOTECH SECTOR: RBC Capit

TipRanks last month

GLPG

GLPGF

PTCT
Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference

DURHAM, N.C., April 01, 2025--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, including gene elimination, gene insertion, and gene excision programs, today announced that management will present at the 24th Annual Needham Virtual Healthcare Conference taking place on April 7, 2025.

Business Wire last month

DTIL
+4.05%
Precision BioSciences (DTIL) Reports Q4 Loss, Misses Revenue Estimates

Precision BioSciences (DTIL) delivered earnings and revenue surprises of -661.90% and 93.28%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

DTIL
+4.05%
Precision BioSciences: Q4 Earnings Snapshot

The Durham, North Carolina-based company said it had a loss of $2.22 per share. Losses, adjusted for non-recurring gains, were $3.20 per share. The genome editing company posted revenue of $638,000 in the period.

Associated Press Finance last month

DTIL
+4.05%
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update

DURHAM, N.C., March 26, 2025--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced financial results for the fourth quarter and fiscal year ended December 31, 2024, and provided a business update.

Business Wire last month

DTIL
+4.05%
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025

DURHAM, N.C., March 21, 2025--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, including gene elimination, gene insertion, and gene excision programs, today announced that it will publish financial results for the fourth quarter and fiscal year 2024 and provide a business update on March 26, 2025.

Business Wire last month

DTIL
+4.05%
Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025

DURHAM, N.C., March 20, 2025--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet diseases, presents preclinical data supporting repeat dosing of PBGENE-HBV in the ELIMINATE-B trial to treat patients with chronic HBV. Even with today’s standard of care, an estimated 15% to 40% of patients with HBV infections may develop complications, such as cirrhosis, liver fai

Business Wire last month

DTIL
+4.05%
Precision BioSciences Presents Preclinical Efficacy and Durability Data on PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy (DMD) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

DURHAM, N.C., March 19, 2025--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, including novel gene excision programs for high unmet need genetic diseases, today announced the presentation of preclinical data for its PBGENE-DMD development program for the treatment of Duchenne muscular dystrophy (DMD) during an oral presentation at the 2025 Muscular Dystrophy Association (M

Business Wire 2 months ago

DTIL
+4.05%
Precision BioSciences Announces Clearance of Investigational New Drug Application by the U.S. FDA for First-in-Class PBGENE-HBV Designed to Eliminate Root Cause of Chronic Hepatitis B

DURHAM, N.C., March 17, 2025--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for PBGENE-HBV. PBGENE-HBV is Precision’s lead wholly owned in vivo gene editing program designed to cure chronic hepatitis B by eliminating ccc

Business Wire 2 months ago

DTIL
+4.05%

Performance Overview

Return	DTIL	S&P 500 (^GSPC)
YTD	+28.08%	+1.00%
1-Year	-61.99%	+11.91%
3-Year	-90.49%	+52.27%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Precision BioSciences, Inc. (DTIL)

Sidoti Events, LLC's Virtual May Micro-Cap Conference

Precision BioSciences (DTIL) Reports Q1 Loss, Lags Revenue Estimates

Precision BioSciences: Q1 Earnings Snapshot

Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update

Precision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025

Precision BioSciences Announces Presentation of Initial Safety Data from the Phase 1 ELIMINATE-B Trial Evaluating PBGENE-HBV at the 2025 European Association for the Study of the Liver Congress (EASL)

Precision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

DTIL Gets FDA's Fast Track Tag for Hepatitis B Gene Therapy, Stock Up

Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B

Biotech stocks slide as Marks resignation seen being negative for sector

Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference

Precision BioSciences (DTIL) Reports Q4 Loss, Misses Revenue Estimates

Precision BioSciences: Q4 Earnings Snapshot

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025

Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025

Precision BioSciences Presents Preclinical Efficacy and Durability Data on PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy (DMD) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Precision BioSciences Announces Clearance of Investigational New Drug Application by the U.S. FDA for First-in-Class PBGENE-HBV Designed to Eliminate Root Cause of Chronic Hepatitis B

Performance Overview